Abstract
This paper shows that selection incentives in downstream markets distort upstream prices. It is possible for inputs to be priced above the value that the good has for final consumers. We apply this idea to pharmaceutical companies selling drugs to a health insurance market with selection problems. We specify the conditions under which drugs are sold at prices exceeding treatment value. Another feature of the model is an excessive private incentive to reduce market size, e.g. in the form of personalized medicine.
Original language | English |
---|---|
Article number | 102868 |
Journal | Journal of Health Economics |
Volume | 94 |
Early online date | Mar 2024 |
DOIs | |
Publication status | Published - Mar 2024 |
Keywords
- selection
- pricing above value
- vertical relations
- pharmaceutical prices